SLC5A2 and chronic kidney disease: In conclusion, SGLT‐2 inhibitors could slow down the deterioration of renal function, regardless of the CKD grades and diabetes, but there was an acute decline of eGFR in the first 2–4 weeks after administration, with a reduction of 4.02 ml/min/1.73 m2 (95% CI, −4.44 to −3.61) compared with baseline eGFR; then the renoprotective effect of SGLT‐2i gradually appeared.